Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Trading Up 0.4% – Time to Buy?

Shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) traded up 0.4% on Tuesday . The company traded as high as $24.13 and last traded at $24.03. 4,000 shares traded hands during mid-day trading, an increase of 92% from the average session volume of 2,082 shares. The stock had previously closed at $23.94.

Amplify Weight Loss Drug & Treatment ETF Trading Up 0.4%

The stock has a 50 day simple moving average of $24.56 and a 200-day simple moving average of $25.19. The firm has a market capitalization of $4.09 million, a P/E ratio of 24.31 and a beta of 0.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC purchased a new position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF at the end of the most recent reporting period.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.